MARKET

ATNM

ATNM

Actinium Pharmac
AMEX
1.050
-0.010
-0.94%
After Hours: 1.050 0 0.00% 16:10 02/23 EST
OPEN
1.050
PREV CLOSE
1.060
HIGH
1.080
LOW
1.030
VOLUME
170.63K
TURNOVER
--
52 WEEK HIGH
2.410
52 WEEK LOW
1.020
MARKET CAP
32.76M
P/E (TTM)
-0.9467
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATNM last week (0216-0220)?
Weekly Report · 14h ago
Actinium To Present Abstracts On ATNM-400 And Actimab-A Programs Across Solid Tumors And Hematologic Oncology Applications At AACR Annual Meeting 2026
Benzinga · 6d ago
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
PR Newswire · 6d ago
Weekly Report: what happened at ATNM last week (0209-0213)?
Weekly Report · 02/16 10:25
Actinium Pharmaceuticals Steve O'Loughlin Resigns As CFO; Sandesh Seth Appointed As CFO
Benzinga · 02/13 22:13
Weekly Report: what happened at ATNM last week (0202-0206)?
Weekly Report · 02/09 10:26
Weekly Report: what happened at ATNM last week (0126-0130)?
Weekly Report · 02/02 10:26
Weekly Report: what happened at ATNM last week (0119-0123)?
Weekly Report · 01/26 10:26
More
About ATNM
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

Webull offers Actinium Pharmaceuticals Inc stock information, including AMEX: ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.